Pertschuk L P, Tobin E H, Brigati D J, Kim D S, Bloom N D, Gaetjens E, Berman P J, Carter A C, Degenshein G A
Cancer. 1978 Mar;41(3):907-11. doi: 10.1002/1097-0142(197803)41:3<907::aid-cncr2820410318>3.0.co;2-v.
Biopsy specimens from 106 women with primary operable, recurrent or metastatic breast cancer were analyzed in a double blind study designed to compare the results of a new fluorescent antibody method for detection of estrogen receptors with estrogen receptors measured biochemically with dextran-coated charcoal and sucrose gradient assay techniques. Assay results correlated in 89.4% of tumors analyzed, and molecular receptor forms (8S and 4S) were accurately predicted in 94.7% of neoplasms studied. Divergent results most often occurred in specimens sparsely populated with malignant cells. The new technique permitted recognition of possible sources of false negative results such as necrosis, absence of tumor and, on occasion, estrogen bound in vivo. It was possible to analyze by the immunofluorescence method two specimens of insufficient size for biochemical assay.
在一项双盲研究中，对106例患有原发性可手术、复发性或转移性乳腺癌的女性的活检标本进行了分析，该研究旨在比较一种用于检测雌激素受体的新型荧光抗体方法的结果与采用葡聚糖包被活性炭和蔗糖梯度分析技术进行生化测定的雌激素受体结果。在分析的89.4%的肿瘤中，检测结果具有相关性，在研究的94.7%的肿瘤中准确预测了分子受体形式（8S和4S）。不同的结果最常出现在恶性细胞稀少的标本中。这项新技术能够识别可能导致假阴性结果的来源，如坏死、无肿瘤以及偶尔出现的体内结合雌激素的情况。通过免疫荧光法可以分析两个生化检测样本量不足的标本。
